AstraZeneca to receive up to $400 million to co-develop Parkinson’s drug

News

Author: Parkinson's Life editorsPublished: 31 August 2017

Parkinson's LifePrep: Parkinson's LifeCook: Parkinson's LifeServes:

AstraZeneca and Takeda lead

AstraZeneca is to receive up to $400 million from Takeda Pharmaceutical after agreeing a deal to co-develop an early-stage medicine for Parkinson’s disease.

The drug, MEDI1341, is an antibody treatment and is due to enter phase I clinical trials later this year.

Mene Pangalos, executive vice president of AstraZeneca, said: “By combining our scientific expertise and sharing the risks and cost of development, we hope to accelerate the advancement of MEDI1341 as a promising new approach to support the treatment of people with Parkinson’s disease around the world.”

The two companies will share future development and commercialisation costs for MEDI1341 equally, in addition to future revenues.

Go Back

Share this story

Comments


Related articles


scything lead

Health & Fitness

Cutting down grass (and my Parkinson’s symptoms) – one scythe at a time

How grass cutting is helping me keep control of my symptoms

READ MORE
Budapest Balloons

Global update

Parkinson’s Awareness Month 2017: global celebrations

Read our round-up: from Hungary to Nepal, Brazil to Kuwait

READ MORE
Invention

Advances

Watch: Parkinson’s invention goes viral

New invention helps people with restricted mobility get dressed

READ MORE